Abstract
Spur cell anemia, a hemolytic anemia observed in patients with alcoholic cirrhosis, is characterized by unusual erythrocyte morphology and an increased ratio of free cholesterol to phospholipid in the erythrocyte membrane.The prognosis of spur cell anemia is usually extremely poor, however, we describe here a patient with spur cell anemia who was successfully treated with combination therapy consisting of flunarizine, pentoxifylline, and cholestyramine. Initial therapy with flunarizine alone for 6 weeks did not significantly decrease the number of spur cells on peripheral blood smears. So pentoxifylline was added to the regimen.The patient recovered from the anemia, showed remarkable improvement with regard to the hyperbilirubinemia, and the changes were accompanied by a significant decrease in the number of spur cells in peripheral blood smears. To correct the hypercholesterolemia, cholestyramine was added to the regimen, which resulted in a reduction in the serum level of free cholesterol and an increase in the molar ratio of free cholesterol to phospholipid in erythrocyte membrane. However, 6 months later a skin eruption developed that was considered an adverse reaction to the drugs, so the flunarizine and pentoxifylline were discontinued. With cholestyramine therapy alone, the remission of spur cell anemia was maintained for more than 11 months. These observations suggest that non-invasive combination therapy with flunarizine, pentoxifylline, and cholestyramine is effective and valuable in the treatment of patients with spur cell anemia.
Similar content being viewed by others
References
Smith JA, Lonergan ET, Sterling K. Spur cell anemia. Hemolytic anemia with red cell resembling acanthocyte in alcoholic cirrhosis.N Engl J Med. 1964;271:396–398.
Cooper RA, Puray MD, Land P, Greenberg MS. An analysis of lipoproteins, bile acids, and red cell membranes associated with target cells and spur cells in patients with liver disease.J Clin Invest. 1972;51:3182–3192.
Allen DW, Manning N. Cholesterol-loading of membranes of normal erythrocytes inhibits phospholipid repair and arachidonoyl- CoA:1-palmitoyl-sn-glycero-3-phosphocholine acyl transferase: a model of spur cell anemia.Blood. 1996;87:3489–3493.
Fukuda T, Baba Y, Tanaka M, et al. Severe alcoholic cirrhosis associated with spur cell anemia and DIC.Fukuoka Igaku Zasshi. 1991;82:398–402.
Doll DC, Doll NJ. Spur cell anemia.South Med J. 1982;75:1205–1210.
Thomson A, Kerlin P, Clouston A, Cobcroft R. Spur cell anaemia resolves after orthotopic liver transplantation (OLT).Aust N Z J Med. 1997;27:198–199.
Chitale AA, Sterling RK, Post AB, Silver BJ, Mulligan DC, Schulak JA. Resolution of spur cell anemia with liver transplantation. A case report and review of the literature.Transplantation. 1998;65:993–995.
Fossaluzza V, Rossi P. Flunarizine treatment for spur cell anemia.Br J Hematol. 1983;55:715–717.
Nishio T, Toshima Y, Matsuno Y. Effects of pentoxifylline on cell shape, ATP content and deformability in rabbit erythrocytes under hyperosmolar conditions.Int J Biochem. 1982;14:915–920
Conrad ME, Barton JC. Anemia and iron kinetics in alcoholism.Semin Hematol. 1980;17:149–163.
Zieve L. Jaundice, hyperlipemia and hemolytic anemia: a heretofore unrecognized syndrome associated with alcoholic fatty liver and cirrhosis.Ann Intern Med. 1958;48:471–496
Clemens MR, Einsele H, Remmer H. Alcohol consumption and hepatic fibrosis affect the fatty acid composition of red blood cells and their susceptibility to lipid peroxidation.Arch Toxicol. 1987;60:167–169.
Cooper RA, Kimball DB, Durocher JR. Role of the spleen in membrane conditioning and hemolysis of spur cells in liver disease.N Engl J Med. 1974;290:1279–1284.
Balistreri WF, Leslie MH, Cooper RA. Increased cholesterol and decreased fluidity of red cell membranes (spur cell anemia) in progresive intrahepatic cholestasis.Pediatrics. 1981;67:461–466.
Takakura Y, Mohandas N. Modulation of erythrocyte membrane material properties by Ca2+ and calmodulin. Implications for their role in regulation of skeletal protein interactions.J Clin Invest. 1988;82:394–400.
Scott CK, Persico FJ, Carpenter K, Chasin M. The effects on flunarizine, a new calcium antagonist, on human red blood cells in vitro.Angiology. 1980;31:320–330.
Morse EE. Mechanisms of hemolysis in liver disease.Ann Clin Lab Sci. 1990;20:169–174.
Yasuhara H,Tonooka M, Kamei K, Sakamoto K. Membrane effect of various drugs on isolated hepatocytes and erythrocytes.Toxicol Appl Pharmacol. 1985;79:453–460.
Angelin B, Bjorkhem I, Einarsson K, Ewerth S. Cholestyramine treatment reduces postprandial but not fasting serum bile acid levels in humans.Gastroenterology. 1982;83:1097–1101.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Aihara, Ki., Azuma, H., Ikeda, Y. et al. Successful Combination Therapy—Flunarizine, Pentoxifylline, and Cholestyramine— for Spur Cell Anemia. Int J Hematol 73, 351–355 (2001). https://doi.org/10.1007/BF02981961
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02981961